您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > BNTA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BNTA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BNTA图片
规格:98%
分子量:456.76
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
BNTA是一种有效的细胞外基质(ECM)调节剂,通过激活超氧化物歧化酶3(SOD3)促进软骨细胞上软骨结构分子的合成。BNTA促进软骨细胞外基质的生成并抑制骨关节炎的发展。BNTA可用于骨关节炎的研究。
货号:ajcx30290
CAS:685119-25-9
分子式:C17H11BrClNO3S2
分子量:456.76
溶解度:DMSO : 50 mg/mL
纯度:98%
存储:Store at -20°C
库存:现货

Background:

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. BNTA has the potential for the research of osteoarthritis[1].

BNTA (0.01-10 μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes[1].BNTA (0.1 μM; 2 d) increases SOX9 protein markedly[1].BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes[1].BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells[1].BNTA (0.01-10 μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes[1].BNTA (0.01-10 μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1 μM in IL1β-induced rat OA chondrocytes[1].BNTA (0.01-1 μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants[1]. Cell Viability Assay[1] Cell Line: Human OA chondrocytes

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats[1]. Animal Model: Male SD rats weighing 80 g are induced by ACLT[1]

[1]. Shi Y, et, al. A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. Nat Commun. 2019 Apr 23; 10(1): 1914.